Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Nat Commun. 2016 Feb 9;7:10442. doi: 10.1038/ncomms10442.
Nat Commun. 2016.
PMID: 26858125
Free PMC article.
Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.
Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.
Maxwell KN, et al. Among authors: colameco c.
Breast Cancer Res Treat. 2017 Aug;164(3):627-638. doi: 10.1007/s10549-017-4257-x. Epub 2017 May 12.
Breast Cancer Res Treat. 2017.
PMID: 28500398
Free PMC article.
Item in Clipboard
Black breast cancer survivors experience greater upper extremity disability.
Dean LT, DeMichele A, LeBlanc M, Stephens-Shields A, Li SQ, Colameco C, Coursey M, Mao JJ.
Dean LT, et al. Among authors: colameco c.
Breast Cancer Res Treat. 2015 Nov;154(1):117-25. doi: 10.1007/s10549-015-3580-3. Epub 2015 Sep 29.
Breast Cancer Res Treat. 2015.
PMID: 26420404
Free PMC article.
Item in Clipboard
Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.
Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.
Maxwell KN, et al. Among authors: colameco c.
Breast Cancer Res Treat. 2017 Aug;164(3):639-640. doi: 10.1007/s10549-017-4339-9.
Breast Cancer Res Treat. 2017.
PMID: 28653249
No abstract available.
Item in Clipboard
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P.
DeMichele A, et al. Among authors: colameco c.
Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11.
Clin Cancer Res. 2015.
PMID: 25501126
Clinical Trial.
Item in Clipboard
Early treatment-related neutropenia predicts response to palbociclib.
McAndrew NP, Dickson MA, Clark AS, Troxel AB, O'Hara MH, Colameco C, Gallager M, Gramlich K, Zafman K, Vaughn D, Schwartz GK, O'Dwyer PJ, DeMichele A.
McAndrew NP, et al. Among authors: colameco c.
Br J Cancer. 2020 Sep;123(6):912-918. doi: 10.1038/s41416-020-0967-7. Epub 2020 Jul 9.
Br J Cancer. 2020.
PMID: 32641862
Free PMC article.
Item in Clipboard
Cite
Cite